| T8685 |
SP-146
|
T8685
|
98%
|
|
|
SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
|
| T6435 |
CCT129202
|
942947-93-5
|
98%
|
|
|
CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively. It is less p...
|
| T6380 |
AMG 900
|
945595-80-2
|
|
|
|
AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases ...
|
| T2611 |
CCT 137690
|
1095382-05-0
|
100%
|
|
|
CCT 137690 is a highly specific and oral-available aurora kinase inhibitor, for aurora A(IC50=15 nM ), B(IC50=25 nM) and C(IC50=19 nM).
|
| T35570 |
Chiauranib
|
1256349-48-0
|
96.25%
|
|
|
Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related k...
|
| T6458 |
CYC-116
|
693228-63-6
|
96.6%
|
|
|
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active a...
|
| T6785 |
BI-847325
|
1207293-36-4
|
97.13%
|
|
|
BI-847325 is a selective dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.
|
| T10215 |
AAPK-25
|
2247919-28-2
|
97.79%
|
|
|
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by...
|
| T2358 |
ENMD-2076
|
934353-76-1
|
98%
|
|
|
ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
|
| T5524 |
Aurora kinase inhibitor-3
|
879127-16-9
|
98%
|
|
|
Aurora kinase inhibitor-3 (Aurora Kinase Inhibitor III) is a potent inhibitor of Aurora A kinase (IC50 = 42 nM).1 It is selective for Aurora A over BMX, BTK, IGF...
|
| TQ0059 |
Ilorasertib
|
1227939-82-3
|
98.03%
|
|
|
Ilorasertib (ABT-348) (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It als...
|
| T16359 |
NU6140
|
444723-13-1
|
98.04%
|
|
|
NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A ...
|
| T6532 |
Hesperadin
|
422513-13-1
|
98.04%
|
|
|
Hesperadin(IC50=250 nM) effectively inhibits Aurora B. It potently reduces the activity of AMPK, MAPKAP-K1, MKK1, Lck, CHK1 and PHK, but it could not inhibit MKK...
|
| T21981 |
Phthalazinone pyrazole
|
880487-62-7
|
98.22%
|
|
|
Phthalazinone pyrazole is potent, selective, and orally bioavailable inhibitor of Aurora-A kinase. Aurora-A is overexpressed in a variety of tumor types and disp...
|
| T2620 |
G-749
|
1457983-28-6
|
98.32%
|
|
|
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
|
| T6028 |
PF 477736
|
952021-60-2
|
98.34%
|
|
|
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CS...
|
| T12010 |
Aurora B inhibitor 1
|
937276-52-3
|
98.37%
|
|
|
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 uM) with potential anticancer activity for cancer research.
|
| T11961 |
MBM-55S
|
2083624-07-9
|
98.38%
|
|
|
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer ce...
|
| T2094 |
Danusertib
|
827318-97-8
|
98.44%
|
|
|
Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinase...
|
| T2602 |
Barasertib-HQPA
|
722544-51-6
|
98.46%
|
|
|
Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor (IC50: 0.37 nM) and demonstrates ~3,700-fold greater selectivity than Aurora A.
|
